Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease

Summary

Complement C3 is a novel risk factor for cardiovascular disease (CVD), but the underlying mechanism is currently unknown. We determined the associations of the anaphylatoxin C3a, the activation product of C3, and of C3 itself with estimates of atherosclerosis and CVD. We studied associations of C3a and C3 with carotid intima-media thickness (cIMT), ankle-arm blood pressure index (AAIx) and CVD in cross-sectional analyses among 545 participants of the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study (62% men, 59.4 ± 6.9 years) and examined effect modification by smoking. We conducted linear and logistic regression analyses with adjustments for age, sex, glucose metabolism status, lipids, adiposity, renal function, blood pressure, pack-years smoked, physical activity, use of medication and investigated mediation by inflammation. C3a was independently associated with cIMT (β=0.032 mm, [95% confidence interval: 0.004; 0.060]) and AAIx (β=−0.022, [−0.043; −0.001]), but C3 was not. Effect modification by smoking was only observed for CVD (P_smoking*C3a=0.008, P_smoking*C3=0.018), therefore these associations were stratified for smoking behaviour. Both C3a (odds ratio [OR] =2.96, [1.15; 7.62]) and C3 (OR =1.98, [1.21; 3.22]) were independently associated with CVD in heavy smokers. The association of C3 with CVD was independent of C3a. Low-grade inflammation did partially explain the association of C3a with AAIx, but not the other observed associations. This suggests that C3a and C3 have distinct roles in pathways leading to CVD. C3a may promote atherosclerosis and additionally advance CVD in heavy smokers. Conversely, C3 may be associated with CVD in heavy smokers via pathways other than atherosclerosis.

Keywords

Complement - C3 - C3a - atherosclerosis - cardiovascular disease

• References

• 1 Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-460S.
• 2 Szeplaki G, Varga L, Fust G. et al. Role of complement in the pathomechanism of atherosclerotic vascular diseases. Mol Immunol 2009; 46: 2784-2793.
• 3 Oikonomopoulou K, Ricklin D, Ward PA. et al. Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol 2012; 34: 151-165.
• 4 Ricklin D, Hajishengallis G, Yang K. et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-797.
• 5 Onat A, Can G, Rezvani R. et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011; 412: 1171-1179.
• 6 Hertle E, Van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012; 55: 881-884.
• 7 Van Greevenbroek MM, Jacobs M, Van Der Kallen CJ. et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 2012; 154: 158-162.
• 8 Yin W, Ghebrehiwet B, Weksler B. et al. Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress. Thromb Res 2008; 122: 221-228.
• 9 Kew RR, Ghebrehiwet B, Janoff A. Characterization of the third component of complement (C3) after activation by cigarette smoke. Clin Immunol Immunopathol 1987; 44: 248-258.
• 10 Helske S, Oksjoki R, Lindstedt KA. et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008; 196: 190-200.
• 11 Phillips CM, Kesse-Guyot E, Ahluwalia N. et al. Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis 2012; 220: 513-519.
• 12 Klos A, Tenner AJ, Johswich KO. et al. The role of the anaphylatoxins in health and disease. Mol Immunol 2009; 46: 2753-2766.
• 13 Cianflone K, Zhang XJ, Genest Jr J. et al. Plasma acylation-stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 1239-1244.
• 14 Kruijshoop M, Feskens EJ, Blaak EE. et al. Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 2004; 341: 33-40.
• 15 Potier L, Abi Khalil C, Mohammedi K. et al. Use and utility of ankle brachial index in patients with diabetes. Eur J Vasc Endovasc Surg 2011; 41: 110-116.
• 16 Atsma F, Bartelink ML, Grobbee DE. et al. Best reproducibility of the ankle-arm index was calculated using Doppler and dividing highest ankle pressure by highest arm pressure. J Clin Epidemiol 2005; 58: 1282-1288.
• 17 Engelen L, Ferreira I, Gaens KH. et al. The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. J Hypertens 2010; 28: 285-293.
• 18 Jacobs M, Van Greevenbroek MM, Van Der Kallen CJ. et al. The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Invest 2011; 41: 167-175.
• 19 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553.
• 20 Van Greevenbroek MM, Jacobs M, Van Der Kallen CJ. et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest 2011; 41: 372-379.
• 21 Wendel-Vos GC, Schuit AJ, Saris WH. et al. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 2003; 56: 1163-1169.
• 22 Kemper H, Ooijendijk W, Stiggelbout M. Consensus over de Nederlandse Norm voor Gezond Bewegen. Tijdschr Soc Gezondheidsz 2000; 78: 180-183.
• 23 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glo-merular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
• 24 Jacobs M, Van Greevenbroek MM, Van Der Kallen CJ. et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009; 39: 437-444.
• 25 Van Bussel BC, Ferreira I, Van De Waarenburg MP. et al. Multiple Inflammatory Biomarker Detection in a Prospective Cohort Study: A Cross-Validation between Well-Established Single-Biomarker Techniques and an Electrochemi-luminescense-Based Multi-Array Platform. PLoS ONE 2013; 08: e58576.
• 26 Thewissen MM, Damoiseaux JG, Duijvestijn AM. et al. Abdominal fat mass is associated with adaptive immune activation: the CODAM Study. Obesity 2011; 19: 1690-1698.
• 27 Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 2008; 40: 879-891.
• 28 Wlazlo N, Van Greevenbroek MM, Ferreira I. et al. Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012; 61: 1787-1796.
• 29 Cole SR, Platt RW, Schisterman EF. et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol 2010; 39: 417-420.
• 30 Muscari A, Bastagi L, Poggiopollini G. et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc Drugs Ther 2001; 15: 453-458.
• 31 Kostner KM, Fahti RB, Case C. et al. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 2006; 365: 129-134.
• 32 Gombos T, Forhecz Z, Pozsonyi Z. et al. Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin Res Cardiol 2012; 101: 607-615.
• 33 Speidl WS, Katsaros KM, Kastl SP. et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. Atherosclerosis 2010; 208: 285-289.
• 34 De Pergola G, Ciccone MM, Guida P. et al. Relationship between C3 Levels and Common Carotid Intima-Media Thickness in Overweight and Obese Patients. Obes Facts 2011; 04: 159-163.
• 35 Thompson T, Sutton-Tyrrell K, Wildman RP. et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008; 58: 835-842.
• 36 Rua-Figueroa I, Arencibia-Mireles O, Elvira M. et al. Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythema-tosus: a 2-year longitudinal study. Ann Rheum Dis 2010; 69: 1136-1139.
• 37 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hy-pofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
• 38 Oksjoki R, Laine P, Helske S. et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007; 195: 90-99.
• 39 Han Y, Fukuda N, Ueno T. et al. Role of complement 3a in the synthetic phenotype and angiotensin II-production in vascular smooth muscle cells from spontaneously hypertensive rats. Am J Hypertens 2012; 25: 284-289.
• 40 Monsinjon T, Gasque P, Chan P. et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17: 1003-1014.
• 41 Li YT, He B, Wang YZ. Exposure to cigarette smoke upregulates AP-1 activity and induces TNF-alpha overexpression in mouse lungs. Inhal Toxicol 2009; 21: 641-647.
• 42 Schaefer M, Konrad S, Thalmann J. et al. The transcription factors AP-1 and Ets are regulators of C3a receptor expression. J Biol Chem 2005; 280: 42113-42123.
• 43 Nilsson B, Nilsson Ekdahl K. tThe tick-over theory revisited: Is C3 a contact-activated protein?. Immunobiology 2012; 217: 1106-1110.
• 44 Saggu G, Cortes C, Emch HN. et al. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol 2013; 190: 6457-6467.
• 45 Howes JM, Richardson VR, Smith KA. et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 09: 216-225.
• 46 Nikolajsen CL, Scavenius C, Enghild JJ. Human complement C3 is a substrate for transglutaminases A functional link between non-protease-based members of the coagulation and complement cascades. Biochemistry 2012; 51: 4735-4742.
• 47 Maclaren R, Cui W, Cianflone K. Adipokines and the immune system: an adipo-centric view. Adv Exp Med Biol 2008; 632: 1-21.
• 48 Cianflone K, Paglialunga S, Roy C. Intestinally derived lipids: metabolic regulation and consequences--an overview. Atheroscler Suppl 2008; 09: 63-68.
• 49 Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609: 127-143.
• 50 Yang X, Peterson L, Thieringer R. et al. Identification and validation of genes affecting aortic lesions in mice. J Clin Invest 2010; 120: 2414-2422.
• 51 Sakuma M, Morooka T, Wang Y. et al. The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury. Arterioscler Thromb Vasc Biol 2010; 30: 1196-1202.
• 52 Peng Q, Li K, Sacks SH. et al. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets 2009; 08: 236-246.